Company Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States.
Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria.
The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma.
It has a collaboration agreement with F.
Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc.
Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Sep 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Antoine Awad |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts United States | |
| Website | https://www.synlogictx.com |
Stock Details
| Ticker Symbol | SYBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001527599 |
| CUSIP Number | 87166L100 |
| ISIN Number | US87166L2097 |
| Employer ID | 26-1824804 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ajay Munshi | Vice President of Corporate Development |
| Antoine Awad | Principal Executive Officer |
| Dr. James J. Collins Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Advisor |
| Dr. Neal Sondheimer M.D., Ph.D. | Vice President & Head of Clinical |
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mary Beth Dooley | Vice President, Head of Finance and Principal Financial Officer & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | S-8 | Filing |
| Nov 12, 2024 | S-8 | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 06, 2024 | DEF 14A | Filing |
| Nov 05, 2024 | ARS | Filing |